XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUE RECOGNITION Revenue Recognition (Notes)
 9 Months Ended
Sep. 30, 2021
Revenue Recognition [Abstract]  
Revenue from Contract with Customer [Text Block] REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2021202020212020
Net product sales$11,243 $10,197 $33,446 $30,555 
Alliance revenues194 184 495 452 
Other revenues187 159 459 443 
Total Revenues$11,624 $10,540 $34,400 $31,450 

Products are sold principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, directly to retailers, hospitals, clinics and government agencies. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of control of the product to the customer. The transfer occurs either upon shipment, upon receipt of the product after considering when the customer obtains legal title to the product, or upon infusion for cell therapies and when BMS obtains a right of payment. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.

The following table summarizes GTN adjustments:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2021202020212020
Gross product sales$17,335 $15,211 $49,676 $43,685 
GTN adjustments(a)
Charge-backs and cash discounts(1,908)(1,440)(5,214)(4,072)
Medicaid and Medicare rebates(2,625)(2,146)(6,482)(5,126)
Other rebates, returns, discounts and adjustments(1,559)(1,428)(4,534)(3,932)
Total GTN adjustments(6,092)(5,014)(16,230)(13,130)
Net product sales$11,243 $10,197 $33,446 $30,555 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $10 million and $282 million for the three and nine months ended September 30, 2021, and $(25) million and $91 million for the three and nine months ended September 30, 2020, respectively.
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2021202020212020
Prioritized Brands
Revlimid$3,347 $3,027 $9,493 $8,826 
Eliquis2,413 2,095 8,091 6,899 
Opdivo1,905 1,780 5,535 5,199 
Orencia870 826 2,442 2,290 
Pomalyst/Imnovid851 777 2,478 2,235 
Sprycel551 544 1,562 1,576 
Yervoy515 446 1,481 1,211 
Abraxane266 342 876 950 
Empliciti82 96 253 290 
Reblozyl160 96 400 159 
Inrebic22 13 54 40 
Onureg21 3 48 3 
Zeposia40 2 86 3 
Breyanzi30 — 47 — 
Abecma71 — 95 — 
Established Brands
Vidaza36 106 135 390 
Baraclude105 100 327 343 
Other Brands339 287 997 1,036 
Total Revenues$11,624 $10,540 $34,400 $31,450 
United States$7,296 $6,542 $21,694 $19,795 
Europe2,661 2,453 7,903 7,156 
Rest of the World1,391 1,361 4,172 4,030 
Other(a)
276 184 631 469 
Total Revenues$11,624 $10,540 $34,400 $31,450 
(a)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $73 million and $463 million for the three and nine months ended September 30, 2021 and $32 million and $260 million for the three and nine months ended September 30, 2020, respectively, consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties for out-licensing arrangements. Contract assets were not material at September 30, 2021 and December 31, 2020.